课题基金 / 基金详情

PSA AS AN INTERMEDIATE MARKER FOR PROSTATE CANCER

PSA AS AN INTERMEDIATE MARKER FOR PROSTATE CANCER
PSA 作为前列腺癌的中间标志物
批准号:
2099921
负责人:
LARRY C CLARK
金额:
$38.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-09-24 至 1996-07-31

项目摘要

项目成果

LARRY C CLARK的其他基金

相似基金

相关文献

中文摘要
翻译
前列腺癌仍然是癌症相关死亡的主要原因
英文摘要
Prostate cancer continues to be a leading cause of cancer-related death in the United States. Identifying the means for preventing the disease and establishing its earlier diagnosis are essential for reducing mortality from prostate cancer and are, therefore, of utmost importance. This project will test the hypothesis that serial measurement of prostate specific antigen (PSA) is an intermediate marker for prostate cancer. It will also test, in a pair of ongoing randomized, double-blind cancer prevention trials using the micronutrient selenium (Sc), the hypothesis that Se supplementation reduces the incidence of either serially increasing PSA levels or prostate cancer. The design of this study is ambi-directional. The retrospective portion will measure PSA levels in the frozen serum samples of 1,000 men in the ongoing cancer prevention trials. Three PSA levels will be determined and subjects with positive PSA levels (a PSA of >4.0 ng/ml or an annual positive trend of >0.75 ng/ml) will be referred for follow up and the resultant documentation will be obtained. The prospective portion will consist of two cohorts:with a total of 1,000 men from the two cancer prevention trials from the low Sc areas of the U.S. The combination of these two cohorts will provide for a wide distribution of plasma Sc levels. The first cohort will have semi-annual PSA, Sc, for a wide distribution of plasma Sc levels. The first cohort will have semi-annual PSA, Sc, micronutrients, testosterone, and prolactin measurements. Subject with positive PSA levels will be referred for follow up and the resultant documentation will be obtained. An estimated 250 cases of elevated PSA levels and 101 cases of prostate cancer will be reported in eh course of this study. These numbers will afford this project the statistical power to detect a 30% reduction in the median time to failure for PSA and a 42% reduction in median time to failure for prostate cancer, in a two-tailed test at 80% power and an alpha=.05.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II CHEMOPREVENTION TRIAL OF SE AND PROSTATE CANCER
  • 批准号:
    2703575
  • 项目类别:
  • 资助金额:
    $80.17万
  • 财政年份:
    1998
  • 负责人:
    LARRY C CLARK
  • 依托单位:
PSA AS AN INTERMEDIATE MARKER FOR PROSTATIC CANCER
  • 批准号:
    3550003
  • 项目类别:
  • 资助金额:
    $36.12万
  • 财政年份:
    1993
  • 负责人:
    LARRY C CLARK
  • 依托单位:
PSA AS AN INTERMEDIATE MARKER FOR PROSTATE CANCER
  • 批准号:
    2099922
  • 项目类别:
  • 资助金额:
    $37.34万
  • 财政年份:
    1993
  • 负责人:
    LARRY C CLARK
  • 依托单位:
NUTRITIONAL PREVENTION OF SKIN CANCER SUPPLEMENT
  • 批准号:
    3194007
  • 项目类别:
  • 资助金额:
    $11.03万
  • 财政年份:
    1988
  • 负责人:
    LARRY C CLARK
  • 依托单位:
国内基金
海外基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
  • 批准号:
    61602201
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2016
  • 负责人:
    周雄辉
  • 依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
  • 批准号:
    81170309
  • 项目类别:
    面上项目
  • 资助金额:
    50.0万元
  • 批准年份:
    2011
  • 负责人:
    颜桥
  • 依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
  • 批准号:
    30672394
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2006
  • 负责人:
    陆豪杰
  • 依托单位: